Prognostic value of HIF-1α in digestive system malignancies: evidence from a systematic review and meta-analysis.
Digestive system
HIF-1α
Neoplasms
Prognosis
Journal
Gastroenterology and hepatology from bed to bench
ISSN: 2008-2258
Titre abrégé: Gastroenterol Hepatol Bed Bench
Pays: Iran
ID NLM: 101525875
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
12
2021
accepted:
27
02
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
This meta-analysis aimed to evaluate the association of HIF-1α expression with clinicopathological features and overall survival (OS) of patients with digestive system malignancies. Numerous studies have demonstrated that hypoxia-inducible factor-1α (HIF-1α) is abnormally expressed in various solid tumors. However, the clinicopathological features and prognostic value of HIF-1α expression in patients with digestive system malignancies remain controversial. A literature search in PubMed, Web of Science, and Scopus databases was performed to identify all relevant studies published in English until 15 October 2020. The pooled effect was calculated to evaluate the association between HIF-1α expression and clinicopathological features and overall survival in cancer patients. Pooled odds ratios (ORs) or hazard ratios (HRs) with a 95% confidence interval (CI) were calculated using fixed- or random-effects model based on between-study heterogeneity. A total of 44 eligible studies with 5,964 patients were included. The pooled results indicated a positive association of HIF-1α overexpression with poor overall survival (OS) (HR=1.990, 95% CI: 1.615-2.453, This meta-data suggest that HIF-1α expression might serve as an independent prognostic marker and a promising therapeutic target in patients with digestive system malignancies.
Sections du résumé
Aim
UNASSIGNED
This meta-analysis aimed to evaluate the association of HIF-1α expression with clinicopathological features and overall survival (OS) of patients with digestive system malignancies.
Background
UNASSIGNED
Numerous studies have demonstrated that hypoxia-inducible factor-1α (HIF-1α) is abnormally expressed in various solid tumors. However, the clinicopathological features and prognostic value of HIF-1α expression in patients with digestive system malignancies remain controversial.
Methods
UNASSIGNED
A literature search in PubMed, Web of Science, and Scopus databases was performed to identify all relevant studies published in English until 15 October 2020. The pooled effect was calculated to evaluate the association between HIF-1α expression and clinicopathological features and overall survival in cancer patients. Pooled odds ratios (ORs) or hazard ratios (HRs) with a 95% confidence interval (CI) were calculated using fixed- or random-effects model based on between-study heterogeneity.
Results
UNASSIGNED
A total of 44 eligible studies with 5,964 patients were included. The pooled results indicated a positive association of HIF-1α overexpression with poor overall survival (OS) (HR=1.990, 95% CI: 1.615-2.453,
Conclusion
UNASSIGNED
This meta-data suggest that HIF-1α expression might serve as an independent prognostic marker and a promising therapeutic target in patients with digestive system malignancies.
Types de publication
Journal Article
Langues
eng
Pagination
108-119Informations de copyright
©2022 RIGLD, Research Institute for Gastroenterology and Liver Diseases.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Int J Colorectal Dis. 2009 Nov;24(11):1287-96
pubmed: 19529947
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Oncol Lett. 2013 Dec;6(6):1631-1635
pubmed: 24260057
World J Gastroenterol. 2018 Jun 14;24(22):2381-2391
pubmed: 29904245
Genes Dis. 2016 Dec 14;4(1):19-24
pubmed: 30258904
Anticancer Res. 2011 Jun;31(6):2351-9
pubmed: 21737664
Clin Oncol (R Coll Radiol). 2011 Jun;23(5):323-32
pubmed: 20970309
Tumour Biol. 2013 Oct;34(5):2477-87
pubmed: 23857282
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S527-36
pubmed: 23748663
Tumour Biol. 2011 Feb;32(1):159-66
pubmed: 20845004
Therap Adv Gastroenterol. 2010 Jul;3(4):213-20
pubmed: 21180603
J Cell Physiol. 2019 Apr;234(4):5011-5022
pubmed: 30471099
Br J Cancer. 2009 May 19;100(10):1666-73
pubmed: 19436307
Am J Pathol. 2010 May;176(5):2292-301
pubmed: 20363910
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Pathol Res Pract. 2017 Jul;213(7):783-792
pubmed: 28554753
Clin Cancer Res. 2004 Dec 15;10(24):8554-60
pubmed: 15623639
Stat Med. 1988 Aug;7(8):889-94
pubmed: 3413368
Mol Biol Rep. 2012 Feb;39(2):2021-9
pubmed: 21647551
BMC Cancer. 2009 Dec 01;9:418
pubmed: 19948069
Clin Colorectal Cancer. 2006 Jan;5(5):350-3
pubmed: 16512994
Cancer Sci. 2010 Jun;101(6):1557-61
pubmed: 20398057
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Cytokine. 2020 Jan;125:154869
pubmed: 31585311
Br J Cancer. 2003 Sep 15;89(6):1042-7
pubmed: 12966423
J Surg Oncol. 2006 Aug 1;94(2):149-54
pubmed: 16847924
Stat Med. 2002 Nov 30;21(22):3337-51
pubmed: 12407676
Int J Clin Oncol. 2013 Apr;18(2):293-304
pubmed: 22350022
Ann Surg Oncol. 2008 Aug;15(8):2336-44
pubmed: 18521687
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Eur J Cancer. 2004 Aug;40(12):1904-12
pubmed: 15288294
Int J Cancer. 2003 Jun 10;105(2):176-81
pubmed: 12673675
Pathol Oncol Res. 2009 Sep;15(3):487-93
pubmed: 19130303
Dis Markers. 2014;2014:513158
pubmed: 24591761
Eur J Surg Oncol. 2009 Dec;35(12):1286-94
pubmed: 19540709
Biochim Biophys Acta. 2012 Dec;1826(2):272-96
pubmed: 22579961
Br J Cancer. 2007 Jan 15;96(1):95-103
pubmed: 17179985
Nature. 2003 Jun 5;423(6940):593-5
pubmed: 12789320
J Radiat Res. 2011;52(6):821-7
pubmed: 22104271
Dis Markers. 2008;25(3):141-8
pubmed: 19096126
Int J Med Sci. 2019 Oct 21;16(11):1517-1524
pubmed: 31673244
Gastroenterology. 2020 Jul;159(1):335-349.e15
pubmed: 32247694
PLoS One. 2014 Mar 10;9(3):e90678
pubmed: 24614305
Ann Diagn Pathol. 2010 Feb;14(1):23-9
pubmed: 20123453
Oncol Rep. 2004 Nov;12(5):1033-7
pubmed: 15492789
World J Gastroenterol. 2013 Mar 28;19(12):1912-8
pubmed: 23569336
Br J Cancer. 2009 Nov 17;101(10):1749-57
pubmed: 19844231
Transl Oncol. 2018 Apr;11(2):559-566
pubmed: 29525633
Pathol Res Pract. 2018 Dec;214(12):1987-1992
pubmed: 30274686
Gastric Cancer. 2006;9(1):44-9
pubmed: 16557436
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Exp Mol Pathol. 2005 Apr;78(2):123-30
pubmed: 15713437
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Tumour Biol. 2014 May;35(5):4401-9
pubmed: 24425106
Int J Colorectal Dis. 2006 Apr;21(3):248-57
pubmed: 16052307
BMC Cancer. 2009 Dec 10;9:432
pubmed: 20003271
BMC Cancer. 2008 May 01;8:123
pubmed: 18452596
Clin Cancer Res. 2006 Sep 1;12(17):5112-7
pubmed: 16951228
Int J Oncol. 2007 Jun;30(6):1359-67
pubmed: 17487356
Dis Esophagus. 2011 Apr;24(3):177-81
pubmed: 21073615
Jpn J Clin Oncol. 2014 Feb;44(2):159-67
pubmed: 24374892
World J Gastroenterol. 2007 Mar 21;13(11):1680-6
pubmed: 17461470